Hypertension Research最新文献_第6页

Prospective study of primary aldosteronism in acute ischemic stroke: association with small vessel disease. 急性缺血性卒中原发性醛固酮增多症的前瞻性研究：与小血管疾病的关系。

IF 4.6 2区医学

Hypertension Research Pub Date : 2025-08-25 DOI: 10.1038/s41440-025-02351-4

Motohiro Okumura, Takeo Sato, Yuki Tsujimoto, Kenji Yamashiro, Yui Watanabe, Satoshi Matsushima, Tetsuya Shimizu, Taku Gomi, Hideto Kuribayashi, Teppei Komatsu, Kenichi Sakuta, Kenichiro Sakai, Hidetaka Mitsumura, Yasuyuki Iguchi

{"title":"Prospective study of primary aldosteronism in acute ischemic stroke: association with small vessel disease.","authors":"Motohiro Okumura, Takeo Sato, Yuki Tsujimoto, Kenji Yamashiro, Yui Watanabe, Satoshi Matsushima, Tetsuya Shimizu, Taku Gomi, Hideto Kuribayashi, Teppei Komatsu, Kenichi Sakuta, Kenichiro Sakai, Hidetaka Mitsumura, Yasuyuki Iguchi","doi":"10.1038/s41440-025-02351-4","DOIUrl":"10.1038/s41440-025-02351-4","url":null,"abstract":"Primary aldosteronism (PA), characterized by autonomous overproduction of aldosterone, may increase the risk of acute ischemic stroke (AIS) through mechanisms involving oxidative stress and vascular endothelial damage, potentially contributing to cerebral small vessel disease (SVD). This study aimed to determine the prevalence of PA in AIS patients and explore the association between SVD markers and PA. Consecutive AIS patients hospitalized between October 2020 and December 2022 were prospectively enrolled. Positive PA screening was defined as an aldosterone-to-renin ratio >200. Final PA diagnosis was judged by endocrinologists based on positive results from captopril challenge, saline infusion, and furosemide-upright tests performed after a sufficient interval from onset. SVD burden was evaluated using total SVD score, which assesses white matter hyperintensities (periventricular and deep/subcortical), cerebral microbleeds (CMBs; deep, lobar, and infratentorial), perivascular spaces, and old lacunes. Of 130 enrolled patients, 120 were included (78% male; median age, 62 years). PA screening was positive in 28% (33/120), of whom 24% (8/33) were confirmed as definite PA. Total SVD score was significantly associated with positive PA screening (PR 1.261, 95%CI 1.021-1.556, p = 0.031) and definite PA diagnosis (PR 1.946, 95%CI 1.229-3.082, p = 0.005). Severe periventricular hyperintensity (PVH) and deep/lobar CMBs were independently associated with positive PA screening and definite diagnosis (p < 0.05). In AIS patients, PA screening positivity was 28%, and definite PA diagnosis was confirmed in 24% of screening-positive patients. SVD burden, especially PVH and deep/lobar CMBs, is closely associated with PA.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24. 巴司他治疗不受控制和顽固性高血压：BaxHTN、BaxAsia和Bax24 3期临床试验的基本原理和设计

IF 4.6 2区医学

Hypertension Research Pub Date : 2025-08-25 DOI: 10.1038/s41440-025-02297-7

John M Flack, Michel Azizi, Jenifer M Brown, Jamie P Dwyer, Erika S W Jones, Aina S Lihn, Lylian Liu, Daniel S Olsson, Shira Perl, Hirotaka Shibata, Ji-Guang Wang, Ulrica Wilderäng, Janet T Wittes, Bryan Williams

{"title":"Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24.","authors":"John M Flack, Michel Azizi, Jenifer M Brown, Jamie P Dwyer, Erika S W Jones, Aina S Lihn, Lylian Liu, Daniel S Olsson, Shira Perl, Hirotaka Shibata, Ji-Guang Wang, Ulrica Wilderäng, Janet T Wittes, Bryan Williams","doi":"10.1038/s41440-025-02297-7","DOIUrl":"https://doi.org/10.1038/s41440-025-02297-7","url":null,"abstract":"Inappropriately elevated aldosterone is a common feature of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN), and is a major pathophysiological driver of adverse cardiorenal outcomes beyond elevated blood pressure (BP). Baxdrostat is a selective aldosterone synthase inhibitor that has demonstrated dose-dependent seated office systolic BP (SBP) lowering in a Phase 2 trial of patients with rHTN. Here, we report the design of the baxdrostat hypertension Phase 3 program. BaxHTN (NCT06034743), BaxAsia (NCT06344104), and Bax24 (NCT06168409) are randomized, multi-national, double-blind, placebo-controlled Phase 3 trials evaluating the efficacy and safety of baxdrostat 1 and/or 2 mg versus placebo. BaxHTN includes patients with uHTN or rHTN, BaxAsia includes patients with uHTN or rHTN primarily from Asia, and Bax24 includes patients with rHTN. Eligibility criteria include age ≥18 years, mean seated office SBP of ≥140 mmHg to <170 mmHg at screening, and ≥2 antihypertensive treatments of different classes for ≥4 weeks before screening. BaxHTN and BaxAsia have four sequential periods following placebo run-in: 12-week double-blind; 12-week open-label; 8-week randomized withdrawal; 20-week open-label. Bax24 has a placebo run-in and 12-week double-blind period. Primary endpoints are changes from baseline to Week 12 in mean seated office SBP (BaxHTN and BaxAsia) and ambulatory 24-h average SBP (Bax24). Safety and tolerability are also assessed. The Baxdrostat hypertension Phase 3 program will assess efficacy, long-term sustained effect, and safety profile in patients with hypertension across multiple geographies. The trials will evaluate the BP lowering efficacy of aldosterone synthase inhibition as a novel treatment for uHTN and rHTN.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment for patients with unilateral aldosteronism: surgical or medical treatment. 单侧醛固酮增多症的治疗：手术或药物治疗。

IF 4.6 2区医学

Hypertension Research Pub Date : 2025-08-22 DOI: 10.1038/s41440-025-02340-7

Hiroki Kaneko, Hironobu Umakoshi, Yoshihiro Ogawa

引用次数: 0

The impact of obstructive sleep apnea and heart rate on arterial stiffness: results from the Tokyo Sleep Heart Study. 阻塞性睡眠呼吸暂停和心率对动脉硬度的影响：来自东京睡眠心脏研究的结果。

IF 4.6 2区医学

Hypertension Research Pub Date : 2025-08-22 DOI: 10.1038/s41440-025-02334-5

Junya Kani, Kazuki Shiina, Shunichiro Orihara, Takamichi Takahashi, Hiroki Nakano, Masatsune Fujii, Megumu Saito, Chisa Matsumoto, Hirofumi Tomiyama, Kazuhiro Satomi

{"title":"The impact of obstructive sleep apnea and heart rate on arterial stiffness: results from the Tokyo Sleep Heart Study.","authors":"Junya Kani, Kazuki Shiina, Shunichiro Orihara, Takamichi Takahashi, Hiroki Nakano, Masatsune Fujii, Megumu Saito, Chisa Matsumoto, Hirofumi Tomiyama, Kazuhiro Satomi","doi":"10.1038/s41440-025-02334-5","DOIUrl":"10.1038/s41440-025-02334-5","url":null,"abstract":"We examined whether obstructive sleep apnea (OSA) and elevated heart rates (HR) independently increase the arterial stiffness and also the interaction between the two factors in increasing the arterial stiffness in a large Sleep Cohort. A total of 1611 subjects who underwent polysomnography and brachial-ankle pulse wave velocity (baPWV) measurement were included in the analysis. Apnea-hypopnea index (AHI) and heart rate were each categorized into three groups (non-mild: 0/h ≤ AHI < 15/h; moderate: 15/h ≤ AHI < 30/h; severe: ≥30/h; Low: HR < 70 bpm; Medium: 70 ≤ HR < 80 bpm; High: ≥80 bpm), followed by group comparisons. A significant correlation was observed between the AHI and HR. In subjects with AHI < 15, a significant increase in the baPWV was observed along with an increased HR. In subjects with HR < 70 also, a significant increase of the baPWV was observed, along with an increase of the AHI. In a crude model of mediation analysis, the AHI was found to exert a direct and indirect (via HR) effect on the baPWV. After adjustments for the age, sex, BMI, MBP, and medication status, the analysis identified AHI as showing a significant association with the baPWV mediated by the HR, whereas no significant direct relationship was observed between the AHI and the baPWV. In conclusion, in subjects with OSA, the observed increase in arterial stiffness may be mediated by an elevated HR, and therefore, elevated HR may be one of key to increase arterial stiffness in OSA.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Attention to blood pressure cuff sizes is important for home and in-clinic blood pressure measurement 注意血压袖带的大小对家庭和诊所的血压测量都很重要。

IF 4.6 2区医学

Hypertension Research Pub Date : 2025-08-21 DOI: 10.1038/s41440-025-02308-7

Ritu Trivedi, Niamh Chapman, Shiva R. Mishra, Mark R. Nelson, Clara K. Chow, Dean S. Picone

{"title":"Attention to blood pressure cuff sizes is important for home and in-clinic blood pressure measurement","authors":"Ritu Trivedi, Niamh Chapman, Shiva R. Mishra, Mark R. Nelson, Clara K. Chow, Dean S. Picone","doi":"10.1038/s41440-025-02308-7","DOIUrl":"10.1038/s41440-025-02308-7","url":null,"abstract":"Arm circumference determines appropriate blood pressure cuff size, which is critical for accurate measurements. This cross-sectional analysis aimed to assess cuff size needs according to mid-arm circumferences of Australian adults. Based on typical in-clinic cuff sizes, most Australians would require a medium (51.7%) or large (44.5%) cuff, which means that the cuff would need to be changed for almost every second patient. Most home devices are supplied with a standard (22–32 cm) or wide-range (22–42 cm) cuff, these were found to be unsuitable for 9 million adults (48.3%) and over 701,995 adults (3.8%), respectively. Concerningly, the standard cuff size available with commonly used home devices would be unsuitable for large proportions of people in higher cardiovascular risk groups (e.g. hypertension (59.7%), diabetes (66.3%), high cholesterol (55.6%) and obesity (92.3%)). This work highlights attention must be paid to selecting appropriate cuff sizes for accurate blood pressure measurements in-clinic and at home.  Appropriate blood pressure cuff size is critical for accurate measurements. Most Australians require a medium (51.7%) or large (44.5%) cuff meaning the cuff needs to be changed for about every second patient. Yet most home devices are supplied with one cuff size which is not suited to over 700,000 adults.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"48 10","pages":"2719-2724"},"PeriodicalIF":4.6,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41440-025-02308-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expanding the therapeutic frontier: esaxerenone in hypertensive patients with CKD and albuminuria. 拓展治疗前沿：依沙塞隆治疗合并CKD和蛋白尿的高血压患者。

IF 4.6 2区医学

Hypertension Research Pub Date : 2025-08-21 DOI: 10.1038/s41440-025-02313-w

Keizo Kanasaki

引用次数: 0

Impact of exercise on all-cause and cardiovascular mortality in non-dialysis chronic kidney disease: the Japan specific health checkups (J-SHC) study. 运动对非透析慢性肾脏疾病全因死亡率和心血管死亡率的影响：日本特定健康检查（J-SHC）研究

IF 4.6 2区医学

Hypertension Research Pub Date : 2025-08-20 DOI: 10.1038/s41440-025-02335-4

Hikari Tasaki, Takaaki Kosugi, Masahiro Eriguchi, Hisako Yoshida, Takayuki Uemura, Hiroyuki Tamaki, Riri Furuyama, Masatoshi Nishimoto, Masaru Matsui, Ken-Ichi Samejima, Kunitoshi Iseki, Koichi Asahi, Kunihiro Yamagata, Tsuneo Konta, Shouichi Fujimoto, Ichiei Narita, Masato Kasahara, Yugo Shibagaki, Toshiki Moriyama, Masahide Kondo, Tsuyoshi Watanabe, Kazuhiko Tsuruya

{"title":"Impact of exercise on all-cause and cardiovascular mortality in non-dialysis chronic kidney disease: the Japan specific health checkups (J-SHC) study.","authors":"Hikari Tasaki, Takaaki Kosugi, Masahiro Eriguchi, Hisako Yoshida, Takayuki Uemura, Hiroyuki Tamaki, Riri Furuyama, Masatoshi Nishimoto, Masaru Matsui, Ken-Ichi Samejima, Kunitoshi Iseki, Koichi Asahi, Kunihiro Yamagata, Tsuneo Konta, Shouichi Fujimoto, Ichiei Narita, Masato Kasahara, Yugo Shibagaki, Toshiki Moriyama, Masahide Kondo, Tsuyoshi Watanabe, Kazuhiko Tsuruya","doi":"10.1038/s41440-025-02335-4","DOIUrl":"https://doi.org/10.1038/s41440-025-02335-4","url":null,"abstract":"Exercise is well known to reduce the risk of cardiovascular diseases and mortality. However, studies in individuals with chronic kidney disease (CKD) are limited. This study used large population-based data to investigate the differences in the impact of exercise habits on all-cause and cardiovascular mortality between individuals with and without CKD. This study included participants from the Japan Specific Health Checkups (J-SHC) Study conducted between 2008 and 2014. The exposure of interest was self-reported daily exercise habits. The association between exercise habits and all-cause and cardiovascular mortality was examined using Cox regression analysis based on the CKD status. Of the 469,466 participants, 84,508 (18.0%) had CKD, and 39,343 (46.6%) exercised. During the median follow-up period of 44.0 months, 3932 (2.76/1000 person-years) and 1505 (5.09/1000 person-years) participants died in the non-CKD and CKD cohorts, respectively. Exercise habits were associated with a lower risk of all-cause mortality in the non-CKD and CKD cohorts, with adjusted hazard ratios and 95% confidence intervals of 0.80 (0.75-0.86) and 0.70 (0.63-0.78), respectively. The effect of exercise habits on mortality was greater in the CKD group (P for interaction = 0.02). Similar results were observed for cardiovascular mortality. Regular exercise was more strongly associated with decreased all-cause and cardiovascular mortality in individuals with CKD than in those without. Our study highlights the need for individuals with mild CKD to prioritize exercise habits over those without CKD.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Short-duration part-time light work and real-time blood pressure variability in older adults: a pilot observational study using cuffless technology at Expo 2025 Osaka. 在2025年大阪世博会上，一项使用无袖带技术的试点观察研究表明，老年人的短期兼职轻工和实时血压变异性。

IF 4.6 2区医学

Hypertension Research Pub Date : 2025-08-20 DOI: 10.1038/s41440-025-02343-4

Taisuke Ueno, Yoichi Takami, Toshiaki Onza, Hiroshi Yamanoh, Nobuko Agata, Arisa Nakamura, Kosuke Shimizu, Koichi Yamamoto

引用次数: 0

Beyond the kidney: ATRAP and the skin renin-angiotensin system in hypertension 肾外：高血压患者的ATRAP和皮肤肾素-血管紧张素系统。

IF 4.6 2区医学

Hypertension Research Pub Date : 2025-08-18 DOI: 10.1038/s41440-025-02336-3

Wakako Kawarazaki

引用次数: 0

Renal–adipose neural circuit underlies the weight-lowering effects of sodium-glucose co-transporter 2 inhibitors 肾-脂肪神经回路是钠-葡萄糖共转运蛋白2抑制剂减肥作用的基础。